Voyageur Pharmaceuticals Ltd.
VYYRF
$0.13
$0.0218.90%
OTC PK
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.00K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.00K | -- | -- | -- | -- |
| Cost of Revenue | 10.10K | -- | -- | -- | -- |
| Gross Profit | -2.10K | -- | -- | -- | -- |
| SG&A Expenses | 772.30K | 266.50K | 468.20K | 290.60K | 229.10K |
| Depreciation & Amortization | 200.00 | 200.00 | 200.00 | 300.00 | 300.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 782.60K | 266.70K | 468.40K | 290.90K | 229.40K |
| Operating Income | -774.60K | -266.70K | -468.40K | -290.90K | -229.40K |
| Income Before Tax | -951.20K | -387.10K | -571.30K | -333.30K | -262.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -951.20K | -387.10K | -571.30K | -333.30K | -262.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -951.20K | -387.10K | -571.30K | -333.30K | -262.20K |
| EBIT | -774.60K | -266.70K | -468.40K | -290.90K | -229.40K |
| EBITDA | -774.40K | -266.50K | -468.20K | -290.60K | -229.10K |
| EPS Basic | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 167.45M | 161.17M | 155.52M | 139.39M | 139.45M |
| Average Diluted Shares Outstanding | 167.45M | 161.17M | 155.52M | 139.39M | 139.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |